Research graph
References from Immuno-based profiling of knee osteoarthritis patients identifies baseline characteristics associated with positive response to autologous platelet-rich plasma injection at one-year follow-up. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
10.1016/s2665-9913(23)00163-7 · 2023 · External reference
From mechanical triggering to metabolic-inflammatory driving: a new paradigm of knee osteoarthritis pathogenesis
10.3389/fimmu.2026.1833313 · 2026 · External reference
A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting
10.1016/j.semarthrit.2015.11.010 · 2016 · External reference
Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys
10.1016/j.semarthrit.2015.11.009 · 2016 · External reference
Treatment of knee osteoarthritis
2018 · External reference
A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative
10.1016/j.semarthrit.2013.11.012 · 2014 · External reference
Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis
10.1002/art.24925 · 2009 · External reference
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence
10.1016/j.joca.2007.06.014 · 2007 · External reference
Total knee arthroplasty (TKA): when do the risks of TKA overcome the benefits? Double risk of failure in patients up to 65 years old
10.1177/19476035231164733 · 2023 · External reference
Platelet-based injections for knee osteoarthritis: do they work, are they safe
10.1016/j.csm.2024.10.009 · 2025 · External reference
Platelet-rich plasma injections for the management of knee osteoarthritis: the ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios
10.1002/ksa.12320 · 2024 · External reference
The use of injectable orthobiologics for knee osteoarthritis: a European ESSKA-ORBIT consensus. Part 1-blood-derived products (platelet-rich plasma)
10.1002/ksa.12077 · 2024 · External reference
PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration: a meta-analysis of randomized controlled trials
10.1177/03635465241246524 · 2025 · External reference
Platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials
10.1177/0363546520909397 · 2021 · External reference
Safety profile comparison of intra-articular corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based injections for knee osteoarthritis: a systematic review and meta-analysis by the ESSKA Orthobiologics Initiative
10.1002/ksa.70230 · 2025 · External reference
Platelet-rich plasma injections induce disease-modifying effects in the treatment of osteoarthritis in animal models
10.1007/s00167-021-06659-9 · 2021 · External reference
The platelet-rich plasma research ecosystem: from mechanistic insights to precision treatment in knee osteoarthritis
10.1016/j.reth.2025.10.017 · 2025 · External reference
Multimodal immune profiling of peripheral blood to predict the response to intra-articular autologous blood-derived orthobiologic treatment in patients with knee osteoarthritis
10.1016/j.biopha.2025.118674 · 2025 · External reference
NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial
10.1016/j.joca.2013.10.009 · 2014 · External reference
Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee
10.1016/j.joca.2004.04.010 · 2004 · External reference
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited
10.1002/9781444315844.ch7 · 2004 · External reference
CRUSTY: a versatile web platform for the rapid analysis and visualization of high-dimensional flow cytometry data
10.1038/s41467-023-40790-0 · 2023 · External reference
The role of WNT and IL-1 signaling in osteoarthritis: therapeutic implications for platelet-rich plasma therapy
10.3389/fragi.2023.1201019 · 2023 · External reference
Platelet-rich plasma for the management of hip and knee osteoarthritis
10.1007/s11926-017-0652-x · 2017 · External reference
Minimal clinically important difference and patient acceptable symptom state in patients with knee osteoarthritis treated with PRP injection
10.1177/23259671211026242 · 2021 · External reference
The value of serum total oxidant to the antioxidant ratio as a biomarker of knee osteoarthritis
10.1016/j.clnesp.2020.05.019 · 2020 · External reference
Evaluation of prolidase activity and oxidative status in patients with knee osteoarthritis: relationships with radiographic severity and clinical parameters
10.1007/s00296-015-3290-5 · 2015 · External reference
Metabolic factors and oxidative stress in osteoarthritis: a case-control study
10.1080/00365513.2017.1354255 · 2017 · External reference
Growth factor independence 1 ameliorates osteoarthritis by inhibiting chondrocyte ferroptosis via inactivation of MAPK signaling pathway
10.1016/j.jot.2025.07.003 · 2025 · External reference
Lipid peroxidation in osteoarthritis: focusing on 4-hydroxynonenal, malondialdehyde, and ferroptosis
10.1038/s41420-023-01613-9 · 2023 · External reference
Release kinetic of pro- and anti-inflammatory biomolecules from platelet-rich plasma and functional study on osteoarthritis synovial fibroblasts
10.1016/j.jcyt.2020.02.006 · 2020 · External reference
The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer
10.3389/fimmu.2019.00712 · 2019 · External reference
Correction to: The long pentraxin PTX3: a novel serum marker to improve the prediction of osteoporosis and osteoarthritis bonerelated phenotypes
10.1186/s13018-021-02481-8 · 2021 · External reference
Pentraxin 3 regulated by miR-224-5p modulates macrophage reprogramming and exacerbates osteoarthritis associated synovitis by targeting CD32
10.1038/s41419-022-04962-y · 2022 · External reference
CD40L expression allows CD8
10.3389/fimmu.2017.01484 · 2017 · External reference
CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8
10.1186/s12865-023-00547-2 · 2023 · External reference
Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
10.1182/blood.v97.7.1920 · 2001 · External reference
Synovial fluid eotaxin-1 levels may reflect disease progression in primary knee osteoarthritis among elderly Han Chinese: a cross-sectional study
10.1177/1947603518764280 · 2019 · External reference
Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation
10.1002/jcb.20239 · 2004 · External reference
Extensive cytokine analysis in synovial fluid of osteoarthritis patients
10.1016/j.cyto.2021.155546 · 2021 · External reference
Novel use of intraarticular granulocyte colony stimulating factor (hG-CSF) combined with activated autologous peripheral blood stem cells mobilized with systemic hG-CSF: safe and efficient in early osteoarthritis
10.1177/19476035211049562 · 2021 · External reference
Cytokine profiling of molecular endotypes of knee osteoarthritis: insights from the IMI-APPROACH cohort
10.1186/s13075-026-03742-9 · 2026 · External reference
New insights into the natural course of knee osteoarthritis: early regulation of cytokines and growth factors, with emphasis on sex-dependent angiogenesis and tissue remodeling. A pilot study
10.1016/j.joca.2018.05.009 · 2018 · External reference
Platelet-derived growth factor as biomarker of clinical outcome for autologous platelet concentrate therapy in grade I knee osteoarthritis
10.2147/btt.s500522 · 2025 · External reference
The (-765 G→C) promoter variant of the COX-2/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis
10.1136/ard.2009.124040 · 2011 · External reference
Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response
10.1161/01.atv.0000030340.80207.c5 · 2002 · External reference
TGF-β type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis
10.1126/scitranslmed.aan2585 · 2019 · External reference
CCL3 serves as a potential plasma biomarker in knee degeneration (osteoarthritis)
10.1016/j.joca.2015.04.002 · 2015 · External reference
Characterization of the interleukin-17 effect on articular cartilage in a translational model: an explorative study
10.1186/s41927-020-00122-x · 2020 · External reference
Complexity of synovial fluid-derived monocyte-macrophage-lineage cells in knee osteoarthritis
10.1016/j.celrep.2024.115011 · 2024 · External reference
The response of two polar monocyte subsets to inflammation
10.1016/j.biopha.2021.111614 · 2021 · External reference
Immunologic profiling suggests an association between Treg cell dysfunction and pain in knee osteoarthritis
10.1002/art.43437 · 2026 · External reference
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
2025 · External reference
Human blood monocyte subsets: A new gating strategy defined using cell surface markers identified by mass cytometry
10.1161/atvbaha.117.309145 · 2017 · External reference
